Lifesci Capital Weighs in on Prime Medicine FY2025 Earnings

Prime Medicine, Inc. (NYSE:PRME) – Equities research analysts at Lifesci Capital issued their FY2025 EPS estimates for shares of Prime Medicine in a research report issued to clients and investors on Monday, March 2nd. Lifesci Capital analyst T. Pardo-Garcia expects that the company will post earnings of ($1.54) per share for the year. Lifesci Capital has a “Outperform” rating and a $6.00 price target on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. Lifesci Capital also issued estimates for Prime Medicine’s Q4 2025 earnings at ($0.41) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.90) EPS.

A number of other brokerages also recently issued reports on PRME. Chardan Capital lowered their price objective on shares of Prime Medicine from $10.00 to $9.00 and set a “buy” rating for the company in a report on Monday, November 10th. Wedbush restated an “outperform” rating and issued a $8.00 target price on shares of Prime Medicine in a research note on Monday, November 10th. Finally, Citigroup reduced their price target on Prime Medicine from $5.00 to $4.25 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.21.

Prime Medicine Trading Down 4.6%

Shares of Prime Medicine stock opened at $3.93 on Thursday. The business’s 50-day moving average price is $3.82 and its 200-day moving average price is $4.17. The firm has a market capitalization of $709.41 million, a PE ratio of -1.92 and a beta of 2.56. Prime Medicine has a 12 month low of $1.11 and a 12 month high of $6.94.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its stake in shares of Prime Medicine by 1,419.4% in the first quarter. AQR Capital Management LLC now owns 243,795 shares of the company’s stock worth $485,000 after acquiring an additional 227,749 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in Prime Medicine in the 1st quarter worth approximately $101,000. Rhumbline Advisers grew its holdings in Prime Medicine by 13.8% during the 1st quarter. Rhumbline Advisers now owns 81,900 shares of the company’s stock valued at $163,000 after buying an additional 9,944 shares in the last quarter. Savant Capital LLC purchased a new stake in Prime Medicine during the 2nd quarter valued at approximately $37,000. Finally, Creative Planning bought a new stake in shares of Prime Medicine during the second quarter valued at approximately $25,000. Institutional investors own 70.37% of the company’s stock.

About Prime Medicine

Prime Medicine, Inc (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.

Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.